Literature DB >> 20632189

Bridge to surgery using partially covered self-expandable metal stents (PCMS) in malignant biliary stricture: an acceptable paradigm?

George H Pop1, James A Richter, Bryan Sauer, Michele E Rehan, Henry C Ho, Reid B Adams, Todd Bauer, Vanessa M Shami, Melissa S Phillips, Michel Kahaleh.   

Abstract

BACKGROUND AND AIM: Partially covered self-expanding metal stents (PCMS) have been extensively used for palliation of malignant distal biliary stricture. Many centers have been using them as a bridge to surgery (BTS) regardless of resectability with or without eventual neoadjuvant therapy. We analyzed the outcome of all patients receiving PCMS and subsequently referred for surgery in our institution.
METHODS: Our prospectively established pancreaticobiliary database was retrospectively analyzed to retrieve all patients with malignant biliary stricture who underwent PCMS placement and subsequently went for curative surgical attempt at our institution. Cancer type and staging, adverse events related to stent placement or surgery, type of surgery performed, time between stenting and surgery, length of postoperative hospitalization, and postoperative follow-up were recorded.
RESULTS: 27 patients (21 men; median age 66 years, range 39-82 years) received PCMS. Indications for placement included biliary stricture related to pancreatic cancer (n=23) or other malignancies (n=4). Median time between stenting and surgery was 32 days (range 6-569 days). Median time of hospitalization post surgery was 7 days (1-40 days). All patients underwent exploratory laparoscopy, followed in 9 (33.3%) by Whipple procedure with uneventful removal of the PCMS. Eighteen patients (66.6%) had their attempted curative resection terminated early due to intraoperative evidence of metastatic spread, with 8 (30%) patients undergoing peritoneal or liver metastasis biopsy. PCMS were left in place in those 18 patients. Complications related to PCMS in the bridge-to-surgery period included migration (n=2, 7.4%) and tissue overgrowth (n=1, 3.4%), all of them managed by endoscopic removal and replacement with PCMS. Median follow-up post surgery was 210 days (range 9-1,642 days).
CONCLUSION: PCMS are an appropriate BTS option. For resectable patients, PCMS results in biliary drainage and allows for neoadjuvant treatment without portending subsequent curative resection (Whipple). For unresectable patients, long-term biliary drainage is provided by PCMS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632189     DOI: 10.1007/s00464-010-1231-7

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  16 in total

Review 1.  Evidence-based assessment of ERCP approaches to managing pancreaticobiliary malignancies.

Authors:  Carole R Flamm; David H Mark; Naomi Aronson
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

Review 2.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

3.  AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference.

Authors:  Jean-Nicolas Vauthey; Elijah Dixon
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

4.  Efficacy and complications of covered Wallstents in malignant distal biliary obstruction.

Authors:  Michel Kahaleh; Jeffrey Tokar; Mark R Conaway; Andrew Brock; Tri Le; Reid B Adams; Paul Yeaton
Journal:  Gastrointest Endosc       Date:  2005-04       Impact factor: 9.427

Review 5.  Diagnostic approach to pancreatic cancer.

Authors:  J S Barkin; J A Goldstein
Journal:  Gastroenterol Clin North Am       Date:  1999-09       Impact factor: 3.806

6.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

7.  Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.

Authors:  P W Pisters; W A Hudec; J E Lee; I Raijman; S Lahoti; N A Janjan; T A Rich; C H Crane; R Lenzi; R A Wolff; J L Abbruzzese; D B Evans
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

8.  Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy.

Authors:  P Jagannath; V Dhir; S Shrikhande; R C Shah; P Mullerpatan; K M Mohandas
Journal:  Br J Surg       Date:  2005-03       Impact factor: 6.939

9.  Use of expandable metallic biliary stents in resectable pancreatic cancer.

Authors:  Sanjeev M Wasan; William A Ross; Gregg A Staerkel; Jeffrey H Lee
Journal:  Am J Gastroenterol       Date:  2005-09       Impact factor: 10.864

10.  Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

View more
  6 in total

Review 1.  Current status of preoperative biliary drainage.

Authors:  Junko Umeda; Takao Itoi
Journal:  J Gastroenterol       Date:  2015-07-03       Impact factor: 7.527

2.  Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy.

Authors:  Lianne K Cavell; Peter J Allen; Cjloe Vinoya; Anne A Eaton; Mithat Gonen; Hans Gerdes; Robin B Mendelsohn; Michael I D'Angelica; T Peter Kingham; Yuman Fong; Ronald Dematteo; William R Jarnagin; Robert C Kurtz; Mark A Schattner
Journal:  Am J Gastroenterol       Date:  2013-04-02       Impact factor: 10.864

3.  Endoscopic drainage of pancreatic fluid collections using a fully covered expandable metal stent with antimigratory fins.

Authors:  Isaac Raijman; Paul R Tarnasky; Sandeep Patel; Douglas S Fishman; Sri Naveen Surapaneni; Laura Rosenkranz; Jayant P Talreja; Dang Nguyen; Monica Gaidhane; Michel Kahaleh
Journal:  Endosc Ultrasound       Date:  2015 Jul-Sep       Impact factor: 5.628

Review 4.  An Update to Hepatobiliary Stents.

Authors:  Brian T Moy; John W Birk
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

5.  A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study.

Authors:  Kei Saito; Yousuke Nakai; Hiroyuki Isayama; Ryuichi Yamamoto; Kazumichi Kawakubo; Yuzo Kodama; Akio Katanuma; Atsushi Kanno; Masahiro Itonaga; Kazuhiko Koike
Journal:  Gut Liver       Date:  2021-01-15       Impact factor: 4.519

6.  Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable metal stent for biliary drainage during neoadjuvant therapy in patients with pancreatic cancer with obstructive jaundice (PUN-NAC trial).

Authors:  Masaki Kuwatani; Kazumichi Kawakubo; Kazuya Sugimori; Hiroyuki Inoue; Hideki Kamada; Hirotoshi Ishiwatari; Shin Kato; Takuji Iwashita; Makoto Yoshida; Shinichi Hashimoto; Masahiro Itonaga; Yusuke Mizukami; Yusuke Nomura; Akio Katanuma; Naoya Sakamoto
Journal:  BMJ Open       Date:  2021-07-08       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.